<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002116</url>
  </required_header>
  <id_info>
    <org_study_id>218A</org_study_id>
    <secondary_id>GS-93-301</secondary_id>
    <nct_id>NCT00002116</nct_id>
  </id_info>
  <brief_title>A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS</brief_title>
  <official_title>A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerance of topical cidofovir (HPMPC) therapy for refractory&#xD;
      mucocutaneous herpes simplex virus disease in AIDS patients. To determine whether topical&#xD;
      HPMPC therapy can induce re-epithelialization and healing of refractory mucocutaneous herpes&#xD;
      simplex virus disease in AIDS patients. To evaluate the virologic effects of topical HPMPC&#xD;
      therapy on herpes simplex virus shedding from refractory lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomized to receive topical therapy with placebo (vehicle alone) or HPMPC at&#xD;
      either 0.3 or 1.0 percent once daily for 5 days. Patients are assessed to day 15; those with&#xD;
      no significant toxicity are eligible to receive open-label topical HPMPC for up to 6 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>Herpes Simplex</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cidofovir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Antiretroviral therapy with AZT, ddI, ddC, or d4T.&#xD;
&#xD;
          -  Oral trimethoprim/sulfamethoxazole.&#xD;
&#xD;
          -  Dapsone.&#xD;
&#xD;
          -  Atovaquone.&#xD;
&#xD;
          -  Fluconazole.&#xD;
&#xD;
          -  Rifabutin.&#xD;
&#xD;
          -  Clarithromycin.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV seropositivity.&#xD;
&#xD;
          -  Mucocutaneous herpes simplex virus (HSV) infection confirmed by previous viral culture&#xD;
             and persisting without improvement despite at least 10 days of acyclovir at a minimum&#xD;
             dose of 1 g/day (oral) or 15 mg/kg/day (intravenous).&#xD;
&#xD;
          -  Measurable lesions.&#xD;
&#xD;
          -  Consent of parent or guardian if less than 18 years of age.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
        Active medical problems sufficient to hinder study compliance or assessment of treatment&#xD;
        effect.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Acyclovir.&#xD;
&#xD;
          -  Immunomodulators (such as corticosteroids or interferons).&#xD;
&#xD;
          -  Lymphocyte replacement therapy.&#xD;
&#xD;
          -  Biologic response modifiers.&#xD;
&#xD;
          -  Ganciclovir.&#xD;
&#xD;
          -  Foscarnet.&#xD;
&#xD;
          -  Vidarabine.&#xD;
&#xD;
          -  Topical trifluridine.&#xD;
&#xD;
          -  Other investigational drugs (except d4T).&#xD;
&#xD;
          -  Amphotericin.&#xD;
&#xD;
          -  Intravenous therapy for PCP.&#xD;
&#xD;
          -  Chemotherapeutic agents.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 14 days prior to study entry:&#xD;
&#xD;
          -  Immunomodulators (such as corticosteroids or interferons).&#xD;
&#xD;
          -  Lymphocyte replacement therapy.&#xD;
&#xD;
          -  Biologic response modifiers.&#xD;
&#xD;
          -  Ganciclovir.&#xD;
&#xD;
          -  Foscarnet.&#xD;
&#xD;
          -  Vidarabine.&#xD;
&#xD;
          -  Topical trifluridine.&#xD;
&#xD;
          -  Other investigational drugs with potential anti-HSV activity.&#xD;
&#xD;
          -  Amphotericin.&#xD;
&#xD;
          -  Intravenous therapy for PCP.&#xD;
&#xD;
        Excluded within 4 weeks prior to study entry:&#xD;
&#xD;
          -  Chemotherapeutic agents.&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  At least 10 days of prior acyclovir at a minimum dose of 1 g/day (oral) or 15&#xD;
             mg/kg/day (intravenous).&#xD;
&#xD;
        Substance abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Los Angeles County - USC Med Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF - San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Zion Med Ctr / UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Presbyterian - Saint Luke's Med Ctr</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hosp</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of North Carolina Hosps</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Plaza Hosp</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Washington / Viral Disease Clinic</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of British Columbia / Univ Hosp</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Acyclovir-resistant herpes: expanded access available for cidofovir gel (Forvade). AIDS Treat News. 1997 Feb 7;(No 264):5.</citation>
    <PMID>11364104</PMID>
  </reference>
  <verification_date>December 1995</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Herpes Simplex</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>cidofovir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Simplex</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cidofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

